KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Liabilities and Shareholders Equity (2016 - 2025)

Jazz Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $11.7 billion for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 2.94% to $11.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.5 billion through Dec 2025, down 3.11% year-over-year, with the annual reading at $11.7 billion for FY2025, 2.94% down from the prior year.
  • Liabilities and Shareholders Equity was $11.7 billion for Q4 2025 at Jazz Pharmaceuticals, up from $11.4 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $13.2 billion in Q2 2021 and troughed at $6.8 billion in Q1 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $11.4 billion (2024), against an average of $11.3 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 117.8% in 2021 and later dropped 16.78% in 2022.
  • Tracing JAZZ's Liabilities and Shareholders Equity over 5 years: stood at $12.3 billion in 2021, then decreased by 11.9% to $10.8 billion in 2022, then increased by 5.15% to $11.4 billion in 2023, then increased by 5.43% to $12.0 billion in 2024, then dropped by 2.94% to $11.7 billion in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $11.7 billion, $11.4 billion, and $10.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.